News
LBTSF
9.75
NaN%
--
Weekly Report: what happened at LBTSF last week (0602-0606)?
Weekly Report · 6d ago
Weekly Report: what happened at LBTSF last week (0526-0530)?
Weekly Report · 06/02 11:00
Weekly Report: what happened at LBTSF last week (0519-0523)?
Weekly Report · 05/26 11:00
Weekly Report: what happened at LBTSF last week (0512-0516)?
Weekly Report · 05/19 10:52
Weekly Report: what happened at LBTSF last week (0505-0509)?
Weekly Report · 05/12 10:53
Almirall, S.A. reports Q1 results
Seeking Alpha · 05/12 10:14
Weekly Report: what happened at LBTSF last week (0428-0502)?
Weekly Report · 05/05 10:54
Weekly Report: what happened at LBTSF last week (0421-0425)?
Weekly Report · 04/28 11:02
Weekly Report: what happened at LBTSF last week (0414-0418)?
Weekly Report · 04/21 11:02
Weekly Report: what happened at LBTSF last week (0407-0411)?
Weekly Report · 04/14 10:53
Weekly Report: what happened at LBTSF last week (0331-0404)?
Weekly Report · 04/07 10:52
Weekly Report: what happened at LBTSF last week (0324-0328)?
Weekly Report · 03/31 11:02
Weekly Report: what happened at LBTSF last week (0317-0321)?
Weekly Report · 03/24 10:52
Weekly Report: what happened at LBTSF last week (0310-0314)?
Weekly Report · 03/17 11:01
Weekly Report: what happened at LBTSF last week (0303-0307)?
Weekly Report · 03/10 11:02
Eli Lilly posts long-term data for eczema therapy Ebglyss
Seeking Alpha · 03/07 15:39
Weekly Report: what happened at LBTSF last week (0224-0228)?
Weekly Report · 03/03 11:01
Almirall, S.A. reports FY results
Seeking Alpha · 02/25 20:47
Weekly Report: what happened at LBTSF last week (0217-0221)?
Weekly Report · 02/24 11:01
Weekly Report: what happened at LBTSF last week (0210-0214)?
Weekly Report · 02/17 10:59
More
Webull provides a variety of real-time LBTSF stock news. You can receive the latest news about Almirall through multiple platforms. This information may help you make smarter investment decisions.
About LBTSF
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.